Section 4 of 6
Clinical evidence
161 evidence topics · 32 sources
Study summaries
PROSPECT
Objective
Location and study date
Part A data cutoff
Study design
Part A trial design
Eligibility criteria
Part A key eligibility criteria
Part B newly diagnosed population
Treatment
Study outcomes
Rationale for using overall response rate as the primary endpoint
Validation as a surrogate for survival
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
No evidence found.
Results
Participant disposition
Part A ongoing treatment at data cutoff
Baseline characteristics
Efficacy results
Part B efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
Part A enrolled 48 participants in an open-label phase II study. The reported response and survival estimates do not establish comparative benefit against another treatment. Enrollment required an ECOG performance score of 0, 1, or 2, limiting direct applicability to participants with worse performance status. Part A monotherapy results should not be extrapolated to Part B chemotherapy combinations.
ONO-4059-02
Objective
Long-term follow-up assessments
Location and study date
Study design
Eligibility criteria
Eligibility and exclusions
“Eligible patients were those with age ≥ 20 years; histologically diagnosed, previously treated relapsed/refractory PCNSL; a brain lesion with the major axis > 1.0 cm; a KPS score ≥ 70; and expected lifetime ≥ 3 months.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients without B-cell type PCNSL and those with systemic lesions were excluded.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Dose groups and treatment duration
“In the ONO-4059-02 open-label, single-arm, phase 1/2 study (Japanese Registry of Clinical Trials identifier, jRCT2080223590), patients with relapsed/refractory PCNSL were administered oral tirabrutinib q.d. at a dose of 320 or 480 mg, or 480 mg under fasted condition.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The treatment was continued over 28-day cycles until disease progression or unacceptable toxicities were observed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using IPCG overall response rate as the primary endpoint
Central response assessment
Validation as a surrogate for survival
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Safety and efficacy analysis sets
“Safety was assessed in all patients who received ≥ 1 dose of study treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Within the safety set, those who had ≥ 1 measurable lesion before the start of treatment and had ≥ 1 centrally assessed BOR were assessed for the efficacy endpoints.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Two-sided 95% confidence intervals (CIs) were calculated using the Clopper-Pearson method.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Quality-of-life analysis population and statistical testing
“The analysis population consisted of 44 patients from the full analysis set.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The mixed model for repeated measures was used to evaluate the systematic transition of scale change, in which time points (cycles) and participants were used as a repeated fixed factor and a random factor, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The scale changes from baseline over time were evaluated with adjusted P-value using Dunnett’s multiple comparison method and the statistical significance level was set to be .05.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Treatment continuation and subsequent therapy
“The number of patients who continued treatment with tirabrutinib for 6 months, 1, 2, or 3 years was 20, 15, 8, and 6, respectively.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A total of 42 patients (95.5%) terminated treatment (including those who completed study treatment) and 2 patients received ongoing treatment with marketed tirabrutinib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Of 42 patients who terminated tirabrutinib treatment, 32 (72.7%) started to receive subsequent treatment, including 28 (63.6%) who had disease progression under the treatment with tirabrutinib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Baseline characteristics
Age, performance status, and prior treatment
“In the overall population, the median age was 60.0 years (range, 29–86) and the median for KPS scores was 80.0 (range, 70–100).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The median number of previous lines of treatment was 2.0 (range, 1–14).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Three-year follow-up
“The median DOR was 9.2 (95% CI: 1.7–17.2) months in the overall population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 3-year OS rate was 56.7% in the overall population” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Radiological response in the autopsy case
Health-related quality of life and patient-reported outcomes
Reported quality-of-life trajectory
Safety results
Long-term adverse-event incidence
“Any-grade AEs occurred in 38 patients (86.4%) and grade ≥ 3 AEs occurred in 23 patients (52.3%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most frequent any-grade AEs were rash (36.4%), neutropenia (27.3%), leukopenia (25.0%), and lymphopenia (18.2%).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study limitations
Summary
The study was uncontrolled and enrolled 44 participants with KPS scores of at least 70. Results therefore do not establish comparative efficacy or directly characterize participants with lower performance status. Subsequent therapy was reported for 32 participants, limiting attribution of long-term overall survival to tirabrutinib alone. Quality-of-life analyses were exploratory, were not planned when the protocol was fixed, and lacked follow-up after tirabrutinib discontinuation. The autopsy publication describes a participant from this trial, not an independent efficacy cohort.
Exploratory quality-of-life analysis and missing follow-up
“This was an exploratory analysis because the statistical analysis was not planned when the protocol was fixed.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Follow-up data on KPS and QoL after tirabrutinib discontinuation were not obtained, preventing an examination of changes compared to the continuation group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
IGNITE
Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using IPCG progression-free survival as the primary endpoint
Primary and secondary endpoints
“The primary endpoint is progression-free survival” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary endpoint is progression-free survival based on blinded independent review committee (BIRC) per International PCNSL Collaborative Group (IPCG) criteria.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Key secondary endpoints are overall response rate based on BIRC per IPCG criteria and overall survival.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Validation as a surrogate for survival
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
No evidence found.
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
The retained publication describes an ongoing, open-label randomized trial with blinded independent review of progression-free survival. It does not provide comparative efficacy or safety results. Progression-free survival is the primary endpoint; overall survival is a secondary endpoint.
ReSTART (JCOG2314)
Objective
Non-inferiority and functional objectives
“We designed a multicenter, randomized phase II/III trial (JCOG2314) to assess the non-inferiority of tirabrutinib to WBRT in overall survival and its potential to reduce functional deterioration and cognitive impairment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Study design
Eligibility criteria
Selected eligibility criteria
“Histologically proven DLBCL from surgical resection or biopsy of an intracranial lesion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Age: 18 years or older.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Eastern Cooperative Oncology Group performance status of 0–2, or 3 due to tumor-related neurological symptoms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No prior RT for PCNSL.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Treatment
Tirabrutinib treatment
“Tirabrutinib is administered orally at a dose of 480 mg once daily under fasting conditions.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The treatment will be continued until disease progression, unacceptable toxicity, or any other protocol-defined reason for discontinuation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Radiotherapy treatment
“Patients in the RT arm will receive WBRT followed by a local boost to the residual parenchymal lesions after induction therapy.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In total, 40 Gy in 20 fractions will be delivered over ~4 weeks, consisting of 30 Gy in 15 fractions for WBRT (2 Gy per fraction, once daily, 5 days/week), and a subsequent local boost of 10 Gy in 5 fractions (2 Gy per fraction).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using overall survival as the phase III primary endpoint
Overall survival definition and analysis role
“In phase III, the primary endpoint is OS in all randomized patients analyzed on an intent-to-treat basis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“OS is defined as the time from randomization to death from any cause and will be censored on the last day of contact for a surviving patient.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Phase II continuation endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Sample size, margin, and power
“To account for potential loss to follow-up, the planned sample size for phase III is set at 94 patients, including those enrolled in phase II.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“a non-inferiority margin of 5 months (corresponding to a hazard ratio of 1.50)” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“a power of 70% with a one-sided alpha level of 10%” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Analysis populations and phase II stopping rule
“All treated patients, including those who discontinued tirabrutinib for reasons other than disease progression, are included in the analysis population.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In phase III, the primary endpoint is OS in all randomized patients analyzed on an intent-to-treat basis.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Advancement to phase III will proceed only if at least 50% (≥5 of these 10 patients) remain on tirabrutinib without disease progression at 4 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
The protocol describes an open-label comparison in induction-refractory PCNSL, not a completed efficacy analysis. The phase III plan includes 94 participants, a non-inferiority hazard-ratio margin of 1.50, 70% power, and a one-sided alpha of 10%. These design choices require consideration when interpreting any future non-inferiority finding. Overall survival and functional or cognitive outcomes must be distinguished from the phase II four-week treatment-continuation criterion.
Japanese post-marketing surveillance
Objective
Real-world safety and effectiveness objective
“This post-marketing surveillance evaluated the safety and effectiveness of tirabrutinib in patients with relapsed/refractory primary central nervous system lymphoma (r/r PCNSL) in a real-world setting in Japan.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Registration period and observation duration
“All patients with r/r PCNSL who started treatment with tirabrutinib between May 20 and 31 October 2020, were registered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Adverse drug reactions (ADRs) and effectiveness were assessed over 52-weeks from the start of tirabrutinib treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study design
Observational surveillance design
“This was a prospective, non-interventional, observational PMS which evaluated the safety and effectiveness of tirabrutinib over the 52-week period from the first dose in patients with r/r PCNSL in Japan.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eligibility criteria
Treatment
Study outcomes
Rationale for using adverse drug reactions as the safety outcome
Statistical analysis description
Number of participants (Planned and analyzed)
Safety and effectiveness population sizes
“Of the 189 patients assessed for safety, 52.4% were male, the median age was 70.0 years (range 30-88), and 49.2% of patients had a Karnofsky performance status score of ≤60.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Among the 121 patients assessed for effectiveness, the overall response rate evaluated by the treating physicians was 61.2%, and the 365-day survival rate was 69.8%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Description of analysis sets
Analysis-set construction
“After combining 10 transferred patients with the original cases and excluding 43 whose consent for disclosure was not obtained from patients or facilities, 189 patients were included in the safety analysis set.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These 68 patients were excluded from the effectiveness analysis set, hence a total of 121 patients were included in the effectiveness analysis set.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Descriptive analysis and confidence intervals
“Descriptive statistics were used to summarize all patients’ baseline characteristics, treatment status, and safety and effectiveness parameters including ADRs and tumor response.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The 95% confidence intervals were determined by the Clopper-Pearson exact method.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Results
Participant disposition
Registration and case report forms
Baseline characteristics
Safety population baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
This prospective observational surveillance had no randomized comparator. Safety was assessed in 189 participants and effectiveness in 121, so the response rate must not be interpreted using the safety-population denominator. Response was assessed by treating physicians. The 52-week observation period limits assessment of later outcomes.
ROSETTA
Objective
Prolonged-effectiveness subgroup objective
Location and study date
Treatment initiation period
Study design
Retrospective multicenter design
Eligibility criteria
Treatment
Tirabrutinib treatment
Study outcomes
Rationale for using overall response rate as an effectiveness endpoint
Endpoint rationale
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Corrected real-world progression-free survival population
Description of analysis sets
Results
Participant disposition
No evidence found.
Baseline characteristics
Efficacy results
Original interim response and progression-free survival
Corrected real-world progression-free survival figure
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
ROSETTA is a retrospective multicenter study without a randomized comparator. The original interim abstract describes 161 participants, whereas the corrected real-world progression-free survival figure identifies 158. The original median progression-free survival estimate of 11.8 months and the corrected estimate of 11.6 months are retained separately; their populations and analysis versions should not be treated as interchangeable.
Single-center retrospective cohort
Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using time to treatment failure as an effectiveness endpoint
Endpoint rationale
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
Efficacy results
Reported outcomes by disease status
| Measure | Quoted value |
|---|---|
| Complete response, refractory disease: cases | “13” |
| Complete response, recurrent disease: cases | “11” |
| Time to treatment failure, refractory disease: months | “7.9” |
| Time to treatment failure, recurrent disease: months | “14.2” |
| Overall survival, refractory disease: months | “25” |
| Overall survival, recurrent disease: months | “32.4” |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Severe pulmonary and hepatic adverse events
Study limitations
Summary
The cohort included 35 participants treated at one institution between 2020 and 2025. Its retrospective design and separate recurrent and refractory groups limit causal interpretation of differences in treatment-failure and survival estimates. There was no randomized comparator in the reported design.
Taiwan multicenter salvage-treatment cohort
Objective
Location and study date
Study design
Retrospective design
Eligibility criteria
Treatment
Study outcomes
Rationale for using overall response rate as an effectiveness endpoint
Endpoint rationale
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Results
Participant disposition
No evidence found.
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
This retrospective cohort included 18 participants in the safety population and 17 in the effectiveness population. One participant contributed only to the safety analysis. The response estimate and infection proportion therefore have different denominators, and neither establishes comparative benefit or harm against another treatment.
REVEAL
Objective
No evidence found.
Location and study date
No evidence found.
Study design
No evidence found.
Eligibility criteria
No evidence found.
Treatment
No evidence found.
Study outcomes
Rationale for using real-world clinical outcomes as the study outcomes
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
No evidence found.
Description of analysis sets
No evidence found.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
No evidence found.
Treatment when standard therapy is difficult
Objective
Location and study date
No evidence found.
Study design
Eligibility criteria
Reasons standard treatment was difficult
Treatment
Administration for swallowing difficulties
Study outcomes
Rationale for using clinical response as an observed outcome
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Not applicable.
Results
Participant disposition
No evidence found.
Baseline characteristics
Baseline characteristics
| Measure | Quoted value |
|---|---|
| Median age, years | “76”View highlighted excerpt for this quote |
| Median KPS | “40”View highlighted excerpt for this quote |
Efficacy results
Reported response and survival
| Measure | Quoted value |
|---|---|
| Response rate | “100%”View highlighted excerpt for this quote |
| Median survival | “8 months”View highlighted excerpt for this quote |
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
This five-case series describes selected participants for whom standard treatment was difficult because of low KPS, renal dysfunction, or resistance to high-dose methotrexate. The reported 100% response rate is based on five participants and has no concurrent control group. It should not be treated as a population-level comparative efficacy estimate.
Long-term treatment and neurotoxicity case series
Objective
Location and study date
No evidence found.
Study design
Eligibility criteria
Not applicable.
Treatment
Study outcomes
Rationale for using clinical response as an observed outcome
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Not applicable.
Results
Participant disposition
No evidence found.
Baseline characteristics
Efficacy results
Remission and treatment-duration observations
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Long-term neurological safety observations
Study limitations
Summary
Two reported cases had long-term treatment without described neurotoxicity or leukoencephalopathy. This uncontrolled case series cannot establish the incidence of neurological toxicity or comparative neurological safety.
Tirabrutinib rechallenge case report
Objective
Location and study date
No evidence found.
Study design
Eligibility criteria
Not applicable.
Treatment
Study outcomes
Rationale for using clinical response as an observed outcome
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Not applicable.
Results
Participant disposition
No evidence found.
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
A single participant experienced five months of remission after tirabrutinib rechallenge. This observation does not establish the probability of response to rechallenge, an optimal retreatment interval, or comparative benefit.
Pseudoprogression during Tirabrutinib treatment
Objective
Location and study date
No evidence found.
Study design
Eligibility criteria
Not applicable.
Treatment
Study outcomes
Rationale for using radiological response as an observed outcome
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Not applicable.
Results
Participant disposition
No evidence found.
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
This single case describes radiological enlargement followed by re-remission during continued tirabrutinib monotherapy. It does not establish the frequency of pseudoprogression or justify assuming that enlargement during treatment is benign in other participants.
Bridging treatment before autologous transplantation
Objective
Bridging-treatment report
“We herein report a case of relapsed primary DLBCL of the CNS complicated with primary biliary cholangitis, cirrhosis, and pancytopenia that was successfully treated with bridging therapy with tirabrutinib before autologous hematopoietic stem cell transplantation (ASCT).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Location and study date
Study design
Eligibility criteria
Not applicable.
Treatment
Treatment and dosage
“She received tirabrutinib and intravitreal methotrexate for relapsed disease.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Her starting dose of tirabrutinib was 320 mg once a day, and she continued the same dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Study outcomes
Rationale for using clinical response as an observed outcome
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Not applicable.
Results
Participant disposition
Baseline characteristics
Age, presentation, and comorbidities
“A 53-year-old woman was referred to our hospital with a chief complaint of dizziness.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“She had PBC, cirrhosis (Child-Pugh A), and pancytopenia due to hypersplenism as comorbidity.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Efficacy results
Response before and after transplantation
“Her brain lesion was ameliorated after four weeks of tirabrutinib.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No relapse of her lymphoma was noted during the follow-up period of 6 months after ASCT.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
This report concerns one participant who received tirabrutinib together with intravitreal methotrexate and subsequently underwent autologous transplantation. The post-transplant absence of relapse cannot be attributed to tirabrutinib alone. A tolerated 320 mg daily dose in this case does not establish a dosing regimen for other participants with cirrhosis.
Relapsed primary spinal-cord lymphoma case report
Objective
Location and study date
No evidence found.
Study design
Eligibility criteria
Not applicable.
Treatment
Study outcomes
Rationale for using clinical response as an observed outcome
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Not applicable.
Results
Participant disposition
No evidence found.
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
This single case describes remission and 42 months without reported relapse after starting tirabrutinib for primary spinal-cord lymphoma. It does not establish response frequency or comparative benefit in broader PCNSL populations.
Vitreoretinal lymphoma with spinal-cord involvement
Objective
Location and study date
No evidence found.
Study design
Eligibility criteria
Not applicable.
Treatment
Study outcomes
Rationale for using clinical response as an observed outcome
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Not applicable.
Results
Participant disposition
No evidence found.
Baseline characteristics
Disease history and prior therapies
Efficacy results
Temporary treatment response
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
The retained case describes a temporary response in a participant with refractory vitreoretinal lymphoma and spinal-cord recurrence after chemotherapy and whole-brain radiotherapy. It does not provide a generalizable estimate of response duration or comparative efficacy.
Lymphomatosis cerebri case report
Objective
Location and study date
No evidence found.
Study design
Eligibility criteria
Not applicable.
Treatment
Study outcomes
Rationale for using radiological response as an observed outcome
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Not applicable.
Results
Participant disposition
No evidence found.
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
Summary
This single case describes five months of complete radiological resolution after starting tirabrutinib. The observation does not establish response frequency, long-term disease control, or comparative benefit in lymphomatosis cerebri.
Cutaneous adverse-event case series
Objective
Location and study date
Study design
Eligibility criteria
Treatment
Study outcomes
Rationale for using cutaneous adverse events as the safety outcome
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Not applicable.
Results
Participant disposition
Baseline characteristics
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
This single-center case series included seven participants, with skin disorders reported in five and treatment discontinuation because of severe cutaneous adverse events in one. The sample size and lack of a comparator limit estimation of population-level risk and comparative tolerability.
Severe central nervous system fungal infection case report
Objective
Location and study date
No evidence found.
Study design
Eligibility criteria
Not applicable.
Treatment
Study outcomes
Rationale for using fungal infection as an observed safety outcome
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Not applicable.
Results
Participant disposition
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Treatment interruption and hepatic toxicity
Study limitations
Summary
The report describes one participant with Aspergillus encephalitis after tirabrutinib exposure and a subsequent fatal subcortical hemorrhage. A case report can identify a possible safety signal but cannot determine incidence or establish that tirabrutinib alone caused the infection or hemorrhage.
Paranasal sinus aspergillosis case report
Objective
No evidence found.
Location and study date
No evidence found.
Study design
Eligibility criteria
Not applicable.
Treatment
No evidence found.
Study outcomes
Rationale for using fungal infection as an observed safety outcome
Not applicable.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Not applicable.
Results
Participant disposition
No evidence found.
Baseline characteristics
No evidence found.
Efficacy results
No evidence found.
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
No evidence found.
Study limitations
No evidence found.
Suspension administration pharmacokinetic case report
Objective
Location and study date
Location and initial presentation date
Study design
Publication design
Eligibility criteria
Not applicable.
Treatment
Reported daily dose
Study outcomes
Rationale for using plasma Tirabrutinib concentration as an exploratory outcome
Clinical bioequivalence validation
No evidence found.
Statistical analysis description
Number of participants (Planned and analyzed)
Description of analysis sets
Not applicable.
Results
Participant disposition
Discharge after treatment initiation
Baseline characteristics
Efficacy results
Health-related quality of life and patient-reported outcomes
No evidence found.
Safety results
Study limitations
Summary
Comparable measured concentrations in a single case do not establish bioequivalence, a limitation explicitly acknowledged by the authors. No adverse events were observed during suspension administration; this observation does not estimate the frequency of uncommon harms.